Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治相关副作用是常见，但严重到足以停药是罕见。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴多巴激动剂，与第一代多巴激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与多巴D2受体有较高结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

是一种类似多巴的多巴激动剂，与第一代多巴激动剂不同的是没有麦角林结构。的非麦角林结构可说明其与多巴D2受体有较高的结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关副作用是常，严重到足以停药程度是罕。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一多巴多巴激动剂，与第一代多巴激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与多巴D2受体有较高结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴的多巴激动剂，与第一代多巴激动剂不同的是没有麦角。罗匹尼罗的非麦角可以说明其与多巴D2受体有较高的合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴的多巴激，与第一代多巴激同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴D2受体有较高的结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价巴受体激临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴的多巴激，与第一代多巴激同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其与多巴D2受体有较高的结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相作用是常见，但严重到足以停药程度是罕见。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似激动剂，与第一代激动剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与D2受体有较高结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺素释放因子治疗相关副作用是常见，但严重到足以停药程度是罕见。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

巴受剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似多巴多巴剂，与第一代多巴剂不同是没有麦角林结构。罗匹尼罗非麦角林结构可以说明其与多巴D2受有较高结合力。

Adverse effects associated with short-term gonadorelin agonists are common, but are rarely serious enough to require drug withdrawal.

短期促性腺激素释放因子治疗相关的副作用是常见的，但严重到足以停药的程度是罕见的。

OBJECTIVE: To evaluate the efficiency and safety of partial dopamine re ceptor agonist in clinical application.

评价受体激动剂临床应疗效性。

Ropinirole,a dopamine agonist,has similar effect of dopamine but without ergoline structure by which its stronger binding power with dopamine D2 receptor may be explained.

罗匹尼罗是一种类似的激动剂，第一代激动剂不同的是没有麦角林结构。罗匹尼罗的非麦角林结构可以说明其D2受体有较高的结合力。